```
chain nodes :
    19 20 21 22 23 24
                                25
                                   26 28
                                             33 34 35 36 37
ring nodes:
                  5 6 7
                                9 10 11
                                             12 13
                                                      14 15 16 17 18
chain bonds :
    1-19 2-37 3-36 4-33 5-34 6-35 10-19 14-19 17-20 20-21 20-22 22-23 25-26
ring bonds :
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15
    15-16 16-17 17-18
exact/norm bonds :
    13-14 13-18 14-15 14-19 15-16 16-17 17-18 17-20 20-21 20-22 22-23 25-26
exact bonds :
    1-19 2-37 3-36 4-33 5-34 6-35 10-19
normalized bonds:
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems:
    containing 1 : 7 :
G1:CH3, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu, [*1], [*2]
Match level :
    1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 28:CLASS 30:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
```

=>

Uploading 10076448.str

L5 STRUCTURE UPLOADED

=> s 15

SAMPLE SEARCH INITIATED 16:09:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 36 TO ITERATE

100.0% PROCESSED 36 ITERATIONS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS:

360 TO 1080

PROJECTED ANSWERS:

0 TO 0

L6 0 SEA SSS SAM L5

=> s 15 sss full

FULL SEARCH INITIATED 16:09:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 579 TO ITERATE

100.0% PROCESSED 579 ITERATIONS 10 ANSWERS

SEARCH TIME: 00.00.01

L7 10 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION 164.87 165.08

0 ANSWERS

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 16:10:03 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2003 VOL 139 ISS 3 FILE LAST UPDATED: 15 Jul 2003 (20030715/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 17

L8 11 L7

=> d 17 1-11 bib abs hitstr

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y) / N:n

=> d 18 1-11 bib abs hitstr

L8

```
2002:671907 CAPLUS
AN
DN
     137:201336
TI
     A process for the preparation of an optically active 4-(tert-
     butoxycarbonyl) piperazine compound
IN
     Kudo, Junko; Hirata, Norihiko; Yoshida, Tomoyasu
PA
     Sumitomo Chemical Company, Limited, Japan
SO
     Eur. Pat. Appl., 20 pp.
     CODEN: EPXXDW
DT
     Patent
     English
LA
FAN.CNT 1
     PATENT NO.
                      KIND DATE
                                            APPLICATION NO.
                                                             DATE
```

ANSWER 1 OF 11 CAPLUS COPYRIGHT 2003 ACS

Disclosed is a process for the prepn. of I [X = Cl, alkyl, alkoxy group; \* = asym. carbon atom] or a salt thereof. 1-[(4-Chlorophenyl)phenylmethyl]piperazine is converted to the Boc-deriv. (PhMe/water, Boc2O, NaOH, 35.degree.C). D-(+)-O,O'-dibenzoyltartaric acid is added to this intermediate (PhMe/MeOH, 30.degree.). The resulting mixt. is seeded and the tartrate salt of the (-)-piperazine is isolated (70.9% ee) by filtration. The ee of the salt is enriched by recrystn. with seeding. Neutralization of (-)-1-[(4-chlorophenyl)phenylmethyl]-4-(tert-butoxycarbonyl)piperazine D-(+)-O,O'-dibenzoyltartaric acid salt (98.2% ee) affords the free base of the (-)-isomer in 90% yield (98.4% ee). Deprotection is accomplished with EtOAc/HCl to afford (-)-1-[(4-chlorophenyl)phenylmethyl]piperazine dihydrochloride in quant. yield. The current process gives higher enantiomeric excess than prior art.

RN 454217-55-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 454217-56-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, 1,1-dimethylethyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).

RN 454217-57-3 CAPLUS

CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2S,3S)-, compd. with 1,1-dimethylethyl (-)-4-[(4-chlorophenyl)phenylmethyl]-1-piperazinecarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 454217-56-2 CMF C22 H27 Cl N2 O2

Rotation (-).

CM 2

CRN 17026-42-5 CMF C18 H14 O8

Absolute stereochemistry. Rotation (+).

RN 454217-59-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, 1,1-dimethylethyl ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

RN 454217-60-8 CAPLUS

CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with 1,1-dimethylethyl (+)-4-[(4-chlorophenyl)phenylmethyl]-1-piperazinecarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 454217-59-5 CMF C22 H27 Cl N2 O2

Rotation (+).

CM 2

CRN 2743-38-6 CMF C18 H14 O8

Absolute stereochemistry.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 2002:534072 CAPLUS

DN 137:93778

TI Preparation of multibinding H1-histamine receptor antagonists

IN Numerof, Robert P.; Ji, Yu-hua; Griffin, John H.

PA Theravance, Inc., USA

SO U.S., 77 pp. CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

PΙ

CN

PATENT NO. KIND DATE APPLICATION NO. DATE
US 6420560 B1 20020716 US 1999-326627 19990607
US 1999-326627 19990607

PRAI US 1999-326627 OS MARPAT 137:93778

AB Novel multibinding compds., which are multimeric ligands, are disclosed as H1-histamine receptor antagonists. The compds. comprise 2-10 ligands, covalently connected via 1-20 linkers, with each ligand capable of binding to the H1 histamine receptor. Fourteen prophetic examples are given to illustrate the invention. Accordingly, the multibinding compds. and pharmaceutical compns. of this invention are useful in the treatment and prevention of allergic diseases such as rhinitis, urticaria, asthma, and anaphylaxis, and the like.

IT 441787-25-3P

RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of multibinding H1-histamine receptor antagonists contg. nitrogen heterocyclic ligands)

RN 441787-25-3 CAPLUS

1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, 1,4-butanediyl ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

\_\_ C1

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 3 OF 11 CAPLUS COPYRIGHT 2003 ACS L8

ΑN 1982:52334 CAPLUS

DN 96:52334

1-(4-Chlorobenzhydryl)-4-(2,3-bishydroxypropyl)-piperazine, its use as an ΤI antitussive agent, an antihistamine, a sedative, an analgesic and an antiinflammatory agent as well as pharmaceutical preparations containing

Selvi e C. S.p.A., Italy PA

Belg., 18 pp. SO

CODEN: BEXXAL

Patent DT

LA Dutch

FAN.CNT 1			
PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI BE 888811	A2	19810828	BE 1981-59160 19810515
DE 3118162	<b>A1</b>	19820218	DE 1981-3118162 19810507
DE 3118162	C2	19840726	
FR 2482965	<b>A1</b>	19811127	FR 1981-9273 19810508
FR 2482965	B1	19841123	
NL 8102361	Α	19811216	NL 1981-2361 19810513
GB 2076403	Α	19811202	GB 1981-15827 19810522
ES 502429	A1	19820401	ES 1981-502429 19810522
JP 57031678	A2	19820220	JP 1981-78562 19810523
JP 61035189	B4	19860812	
PRAI IT 1980-22283		19800523	
GI			

AB The title compd. was prepd. and found superior to codeine in title activity. Thus, Et 1-piperazinecarboxylate was alkylated with 4-ClC6H4CHPhBr, decarboxylated, and treated with glycidol to give I.


IT 80476-89-7P

> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and decarboxylation of)

RN80476-89-7 CAPLUS

CN1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, ethyl ester (9CI) (CA INDEX NAME)





```
L8
    ANSWER 4 OF 11 CAPLUS COPYRIGHT 2003 ACS
AN
    1976:446748 CAPLUS
    85:46748
DN
    Piperazine derivatives
ΤI
    Cyrus, Richard; Raschack, Manfred
TN
    Knoll A.-G., Fed. Rep. Ger.
PA
    Ger. Offen., 45 pp.
SO
    CODEN: GWXXBX
DT
    Patent
LA
    German
FAN.CNT 1
    PATENT NO.
                  KIND DATE
                                       APPLICATION NO. DATE
    -----
                                       -----
                   A1
                         19760226
PΙ
    DE 2438725
                                       DE 1974-2438725 19740812
                   A1 19760115
                                       BE 1975-158334
    BE 831406
                                                       19750715
    DK 7503259
                   Α
                         19760213
                                       DK 1975-3259
                                                       19750717
                        19810216
                   В
    DK 142871
    DK 142871
                    C
                        19810921
                   A1 19760312
B1 19790810
    FR 2281764
                                       FR 1975-22893
                                                      19750722
    FR 2281764
                   A
                         19761027
    ZA 7504846
                                       ZA 1975-4846
                                                      19750728
                   Α
                        19761207
    US 3996360
                                       US 1975-600870
                                                       19750731
    CS 191940
                   P
                       19790731
                                       CS 1975-5369
                                                       19750731
                   D
                       19771205
    SU 583754
                                       SU 1975-2162172 19750804
                        19770414
    GB 1470362
                    Α
                                       GB 1975-32633
                                                       19750805
                        19760216
    NL 7509427
                    Α
                                                       19750807
                                       NL 1975-9427
                   A1
                                       IL 1975-47890
    IL 47890
                         19791031
                                                       19750807
                   C
A
A
    DD 123340
                                       DD 1975-187771
                         19761212
                                                       19750808
    AT 7506187
                                       AT 1975-6187
                         19770815
                                                       19750808
    NO 7502806
                         19760213
                                       NO 1975-2806
                                                       19750811
    NO 143221
                    В
                         19800922
    NO 143221
                    C
                         19810102
    SE 7508993
                    Α
                         19760213
                                       SE 1975-8993
                                                       19750811
    SE 410455
                    В
                         19791015
    HU 172817
                    P
                         19781228
                                       HU 1975-KO2730
                                                       19750811
    FI 7502281
                    Α
                         19760213
                                       FI 1975-2281
                                                       19750812
                   В
    FI 61698
                         19820531
    FI 61698
                    C
                         19820910
                    A2 19760414
    JP 51043775
                                       JP 1975-98030
                                                       19750812
    AU 7583889
                    A1 19770217
                                       AU 1975-83889
                                                       19750812
    ES 440208
                    A1 19770301
                                       ES 1975-440208
                                                       19750812
    CA 1060446
                    A1 19790814
                                       CA 1975-233316
                                                       19750812
                    Α
    CH 627458
                         19820115
                                       CH 1975-10469
                                                       19750812
                    Α
    US 4031216
                         19770621
                                       US 1976-719105
                                                       19760831
PRAI DE 1974-2438725
                         19740812
    US 1975-600870
                         19750731
GI
```

$$\begin{array}{c|c} \text{MeO} & \text{Z} \\ \text{MeO} & \text{NCHPh} \\ \hline \\ \text{NR1} & \text{I} \end{array}$$

$$\begin{array}{c|c} \text{MeO} & \text{O} \\ \hline \\ \text{MeO} & \text{NH} \\ \hline \\ \text{CH}_2\text{Ph} & \text{II} \\ \end{array}$$

AB Antiarrhythmic (no data) piperazines I (R = H, Cl; R1 = C1-8 alkyl, allyl, CH2CH:CHMe, aminoalkyl, CO2Et, CH2CO2Et, Ac, hydroxyalkyl, CH2CH2O2CC6H2 (OMe) 3-3,4,5,Z=H2) were prepd. by alkylating I (R1 = H,Z=H2) obtained by benzylating 3,4-(MeO) 2C6H3CH2CMe (CO2Me) NHCH2, treating 3,4 (MeO) 2C6H3CH2CMe (CO2Me) NHCH2Ph with CH2O and KCN, cyclizing 3,4-(MeO) 2C6H3CH2CMe (CO2Me) N (CH2Ph) CH2CN, benzylating the piperazinone II, treating the piperazine with BrCHPh2 or ClCHPhC6H4Cl-4, debenzylating I (R1 = CH2Ph,Z = O) (III), and reducing III.

IT 59716-30-2P

RN 59716-30-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-2-[(3,4-dimethoxyphenyl)methyl]-2-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

HC1

L8

ANSWER 5 OF 11 CAPLUS COPYRIGHT 2003 ACS

```
AN ·
    1960:62825 CAPLUS
DN
     54:62825
OREF 54:12169a-h
     Piperazine derivatives
ΤI
     Morren, H. G.
IN
DT
     Patent
LA Unavailable
FAN.CNT 1
     PATENT NO.
                     KIND DATE
                                           APPLICATION NO. DATE
                     ----
PΙ
     BE 549420
                            19570110
                                           BE
     DE 1062248
                                           DΕ
     1-[2-(o-Chlorobenzhydryloxy)ethyl]-4-[2-(2-hydroxyethoxy)ethyl]piperazine,
AB ·
     b0.1 230.degree., was prepd. in 80% yield by heating at 100.degree. for 15
     hrs. a stirred mixt. of 0.1 mole 1-[2-(o-chlorobenzhydryloxy)ethyl]piperaz
     ine (I), 0.11 mole Et3N, and 0.1 mole 2-(2-chloroethoxy)ethanol in 100 cc.
     toluene; di-HCl salt m. 150.degree.. With A = 2-(o-
     chlorobenzhydryloxy)ethyl group, the following derivs. were prepd.:
     1-A-substituted-4-isopropylpiperazine, b0.04 184-6.degree. (di-HCl salt m.
     203.degree.), in 88% yield by refluxing 1 mole 1-isopropylpiperazine, 1.1
     moles Et3N, and 1 mole 2-chloroethyl o-chlorobenzhydryl ether (II) 18 hrs.
     in 600 cc. xylene. 1-A-Substituted-(m-methylbenzyl)piperazine, b0.1
     240.degree. (di-HCl salt m. 224-6.degree.), in 50% yield, by heating under
     N at 160.degree. for 3 hrs., 0.1 mole 1-(m-methylbenzyl)-4-(2-
     hydroxyethyl)piperazine and 0.1 mole o-chlorobenzhydryl chloride.
     1-A-Substituted-4-[2-(p-tert-butylbenzyloxy)ethyl]piperazine, b0.1
     275.degree., in 50% yield from o-chlorobenzhydrol and 1-[2-(p-tert-
     butylbenzyloxy)ethyl]-4-(2-chloroethyl)piperazine at 160.degree. under N
     for 3 hrs. 1-A-Substituted-4-acetylpiperazine (III), b0.02 220.degree. in
     94% yield from I and AcCl in presence of Et3N toluene soln. and similarly
     1-A-substituted-4-(o-chlorobenzoyl)piperazine, b0.1 255.degree. (di-HCl
     salt m. 210-12.degree.). 1-A-Substituted-4-ethylpiperazine, b0.03
     178-80.degree. (di-HCl salt m. 186-8.degree.), in 88% yield, by refluxing
     for 18 hrs. under N, 0.1 mole III, and 0.15 mole LiAlH4 suspended in Et2O.
     1-A-Substituted-4-methylpiperazine, b0.1 185-90.degree. (di-HCl salt m.
     200.degree.), in 95% yield, by treating 0.1 mole I with a soln. of 24 cc.
     40% aq. HCOH in 100 cc. EtOH, and redn. in an autoclave at 60.degree. for
     3 hrs. under 50 kg. H in the presence of Raney Ni. 1-A-Substituted-4-
     butylpiperazine b0.1 210.degree. (di-HCl salt m. 200-3.degree.).
     1-A-Substituted-4-isobutylpiperazine b0.02 188-90.degree..
     1-A-Substituted-4-(2-hydroxyethyl)piperazine b0.1 230.degree.; di-HCl salt
     m. 150.degree.. 1-A-Substituted-4-(2,3-dihydroxypropyl)piperazine
     decompd. on distn.; di-HCl salt m. 147-50.degree.. 1-A-Substituted-4-
     cyclohexylpiperazine b0.05 235-40.degree.; di-HCl salt m. 230-3.degree..
     1-A-Substituted-4-(3-methylcyclohexyl)piperazine b0.01 230-2.degree.;
     di-HCl salt m. 214-15.degree.. 1 A-Substituted-4-benzylpiperazine b0.1
     230-5.degree.; di-HCl salt m. 210.degree.. 1-A-Substituted-4-(o-
     chlorobenzyl)piperazine b0.1 240-1.degree.; di-HCl salt m. 208-9.degree..
     1-A-Substituted-4-(o-methylbenzyl)piperazine b0.005 235.degree..
     1-A-Substituted-4-(p-tert-butylbenzyl)piperazine b0.1 245-50.degree.;
     di-HCl salt m. 212-14.degree.. 1-[2-(o-Methylbenzhydryloxy)ethyl]-4-(o-
     methoxybenzyl)piperazine b0.01 234-6.degree. and the corresponding
     4-isopropyl-, 4-(o-methylbenzyl)-, and 4-(m-methylbenzyl)piperazines resp.
     b0.002 175.degree., b0.01 218-20.degree., and b0.015 224.degree.. II,
     b0.1 143.degree., was obtained in 90% yield from 2-chloroethanol and
     chlorobenzhydrol in presence of H2SO4. Similarly prepd. was 2-chloroethyl
     o-methylbenzhydryl ether, b0.04 137.degree.. I, b0.007 185.degree.
     (di-HCl salt m. 105-7.degree.), was prepd. in 85% yield by refluxing 4
     hrs. anhyd. piperazine (3.5 moles) and 1 mole II in 100 cc. xylene.
```

IT

RN

CN

1-Cyclohexylpiperazine, b12 129-31.degree., was prepd. in 30% yield by refluxing for several hrs. cyclohexyl bromide and excess anhyd. piperazine in xylene. 1-[2-(o-Methylbenzhydryloxy)ethyl]piperazine, b0.005
168-70.degree., 1-(3-methylcyclohexyl)piperazine, b11 132-4.degree., and 1-(o-methylbenzyl)piperazine, b0.1 88.degree., were similarly prepd.
1-(2,3-Dihydroxypropyl)piperazine, b0.1 146.degree., m. 70.degree., was obtained in 40% yield by stirring below 30.degree. for several hrs., 1 mole epoxypropanol and 2 moles piperazine hexahydrate in 750 cc. H2O.
80476-89-7, 1-Piperazinecarboxylic acid, 4-(p-chloro-.alpha.-phenylbenzyl)-, ethyl ester (prepn. of)
80476-89-7 CAPLUS
1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, ethyl

ester (9CI) (CA INDEX NAME)

- L8 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2003 ACS
- AN 1959:122232 CAPLUS
- DN 53:122232
- OREF 53:21986f-i,21987a-g
- Unsymmetrically substituted piperazines. XII. Benzhydrylpiperazines and TT related compounds with spasmolytic and antifibrillatory action
- ΑU Ide, Walter S.; Lorz, Emil; Phillips, Arthur P.; Russell, Peter B.; Baltzly, Richard; Blumfeld, Robert
- CS Wellcome Research Labs., Tuckahoe, NY
- Journal of Organic Chemistry (1959), 24, 459-63 so CODEN: JOCEAH; ISSN: 0022-3263
- DTJournal
- LA Unavailable
- cf. C.A. 50, 4975b; 53, 11394h. In a study of compds. showing activity AΒ against artificial fibrillation, a no. of .omicron.-substituted benzhydrylpiperazines and related benzhydrylamines were prepd. compds. were isolated, in general, by previously described techniques. The choice of mono or dihydrochlorides for the piperazines of the 1st series was largely a matter of convenience. A considerable no. of the mono-HCl salts of benzhydrylpiperazines could be crystd. from H2O and solns. have pH 5-5.5. The di-HCl salts are more readily crystd. from alc.-Et20 than the HCl salts. The following RN(CH2CH2)2NR' were prepd. (R, R', salt, and m.p. of salt given): PhCH(CH2)3Me, Me, di-HCl, 248.degree. (decompn.); PhCH(CH2)4Me, Me, di-HCl, 252.degree. (MeI deriv. m. 119.degree.); PhCHC6H11, Et (I), HCl, 266.degree.; Ph2CH, CHMe2, di-HCl, 218.degree.; MeO2CCH2CH2, Ph2CH, di-HCl, 190-1.degree.; p-H2NC6H4CO, Me, HCl, 238.degree.; p-H2NC6H4CO, PhCH2, di-HCl.2H2O, foams above 100.degree. unmelted at 250.degree.; p-H2NC6H4CO, Ph2CH, di-HCl.2H2O, foams above 100.degree. unmelted at 250.degree.; .omicron.-MeC6H4CHPh, CO2Et, HCl, 206.degree.; .omicron.-MeC6H4CHPh, H, HCl, 246.degree.; m-MeC6H4CHPh, CHMe2, di-HCl, 226.degree.; .omicron.-EtC6H4CHPh, Me, di-HCl, 223-5.degree.; .omicron.-ClC6H4CHPh, CHMe2, HCl, 272.degree.; (.omicron.-MeC6H4)2CH, Me, di-HCl, 235.degree.; (p-MeC6H4)2CH Me (II), HCl, 244-6.degree.; (.omicron.-EtC6H4)2CH, Me, di-HCl, 218.degree.; Ph3C, Me, HCl, 186-91.degree.. The following PhCHRNR2' were obtained (R, NR2', salt, m.p. of salt given): .omicron.-ClC6H4, NHMe, HCl, 214.5-15.0.degree.; .omicron.-ClC6H4, NMe2, HCl, 233-3.5.degree.; ogr;-ClC6H4, NC5H10, HCl, 240-1.degree.; .omicron.-MeC6H4, NC5H10, HCl, 265-6.degree.; .omicron.-MeC6H4, NC4H8O, HCl, 256.degree. (decompn.); .omicron.-ClC6H4, NH(CH2)2NMe2, di-HCl, 183-5.degree.; .omicron.-MeC6H4, NH(CH2)2NMe2, di-HCl, 199-200.degree.; Ph, NH(CH2)2NMe2, di-HCl, 206-7.degree.; Ph, NH(CH2)2NC4H80, di-HCl, 243-4.degree.. The following PhCHRN(CH2)2NR'R2X were obtained (R, R', R2, X, and m.p. given): Ph, Me, C7H15 Br, 183.degree.; p-ClC6H4, Me, C7H15, BrCl, 198.degree.; p-ClC6H4, Me, Cl2H25, BrCl, 156.degree.; C6H11, Me, Me, iodide, 214-15.degree.; C6H11, Me, Et, iodide, 173-4.degree.; C6H11, Me, C3H7, iodide, 182.degree.; C6H11, Me, iso-Pr, iodide, 194.degree.; C6H11, Me, Bu, iodide, 108-10.degree.; C6H11, Et, Et, iodide (III), 195.degree.; C6H11, Et, iso-Pr, iodide, 216.degree.. Hexahydrobenzhydrol (19.1 g.) in 100 cc. PhMe refluxed 1 hr. with 10 cc. SOCl2, left overnight, the volatiles removed, and the residual oil distd. at 1 mm. gave 16 g. hexahydrobenzhydryl chloride (IV), b. 99.5-102.degree.. IV contained no significant amt. of unsatd. hydrocarbon. IV (8.3 g.) refluxed 96 hrs. with 9.1 g. N-ethylpiperazine, the mixt. partitioned between Et20 and H20, the Et20 layer evapd. and shaken with N HCl, and the base liberated gave I. I (1.6 g.) in 10 cc. Me2CO left 1 day with 2 g. EtI gave 1.3 g. III. IV (10 g.) refluxed 23.5 hrs. with 20 g. N-methylpiperazine in 100 cc. MeCN, refrigerated, and sepd. gave 8.4 g. II, m. 244-6.degree. (decompn.) (abs. alc.). Pyrrolidine (10 g.) refluxed 1 hr. with 12.5 g. Ph2CHCOCl in 50 cc. Me2CO gave N-diphenylacetylpyrrolidine (V), m. 162-3.degree.

(Et20-MeOH). V (7.9 g.) refluxed 5 hrs. with 1.5 g. LiAlH4 in 200 cc. Et20, 5 cc. H2O added slowly, the Et20 ext. washed with dil. HCl, and the base liberated from the aq. layer gave N-(.alpha.,.alpha.diphenylethyl)pyrrolidine, m. 174-5.degree. (Me2CO-Et2O). N-Diphenylacetyl-N'-methylpiperazine (8.8 g.) reduced as above with 2.5 g. LiAlH4 gave N-diphenylethyl-N'-methylpiperazine; di-HCl salt m. 256-7.degree. (decompn.). Diphenyl-4-pyridylcarbinol (13 g.) in 150 cc. MeOH refluxed 22 hrs. with 7 cc. MeI gave .alpha.,.alpha. diphenylpyridine-4-methanol methiodide, m. 234-5.degree. (MeOH-Et2O). .alpha.,.alpha.-Diphenylpiperidine-4-methanol (14 g.) with 20 cc. Me acrylate in 25 cc. C6H6 kept 24 hrs. at 45-50.degree., refluxed 5 hrs., and evapd. in vacuo gave .alpha.,.alpha.-diphenyl-1-(carbomethoxyethyl)piperidine-4-methanol, m. 93-4.degree. (C6H6hexane). Methylation of the secondary base with excess MeI and alkali gave .alpha.,.alpha.-diphenyl-1-methylpiperidine-4-methanol-MeI, m. 219-20.degree. (Me2CO then alc.), .omicron.-MeC6H4MgBr (from 3.7 g. Mg and 28 g. .omicron.-MeC6H4Br) treated during 15 min. with 8 g. Me N-methylisonipecotate, left 2 hrs. at room temp., and refluxed 1 hr. gave after treatment with HCl gas 15-17 g. 1-methyl-4-(.omicron.methylbenzoyl)piperidine (VI), m. 183-5.degree. (alc.-Et20). Examn. of the material in the mother liquors gave 2 g. .alpha.,.alpha.-di(.omicron.toly1)-1-methylpiperidine-4-methanol (VII), m. 300-2.degree.. From the mother liquors of the above carbinol more material was obtained, m. 158.degree., which had the compn. of a ketone-HCl, possibly isomeric with VI or a dimorphism effect. VII was recovered after refluxing 2 hrs. with an equal vol. of AcOH or concd. HCl. With concd. H2SO4 on the steam bath VII suffered extensive decompn. Benzhydryl chloride (5 g.) and 7.2 g. N-methyl-N'-(hydroxyethyl)piperazine in a little C6H6 was warmed 3 days on the steam bath, the mixt. partitioned between Et2O and H2O, and the base in the Et2O layer converted into the HCl salt, m. 200.degree.. Treatment of an aq. soln. of the salt with alkali and excess MeI in Et2O gave N-benzhydryloxyethyl-N',N'-dimethylpiperazinium iodide, m. 182-5.degree. (alc. Et20).

RN 112350-85-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(o-methyl-.alpha.-phenylbenzyl)-, ethyl ester, hydrochloride (6CI) (CA INDEX NAME)

HCl

```
ANSWER 7 OF 11 CAPLUS COPYRIGHT 2003 ACS
L8
     1959:40048 CAPLUS
AN
DN
     53:40048
OREF 53:7215f-i,7216a-c
     Piperazine derivatives
ΤI
     Weston, Arthur W.; Hamlin, Kenneth E., Jr.
IN
     Abbott Laboratories
PA
DT
     Patent
     Unavailable
LΑ
FAN.CNT 1
                      KIND DATE
                                            APPLICATION NO. DATE
     PATENT NO.
                      ----
                            -----
                                            _____
PΙ
     US 2861072
                             19581118
                                            US
     For diagram(s), see printed CA Issue.
GΙ
AΒ
     R2R3R4CN.CH2.CH2.NR1.CH2.CH2 (I) were prepd., some of which are useful in
     combating the symptoms of histamine activity while others show
     antispasmodic activity. p-CIC6H4CHPhCl (11.9 g.), 5.0 g.
     N-methylpiperazine, and 5.3 g. Na2CO3 in 75 cc. anhyd. xylene refluxed and
     stirred 60 hrs., the xylene layer extd. several times with dil. HCl, the
     exts. combined, made alk. with NaOH, extd. with Et2O, the exts. combined,
     dried, and treated with gaseous HCl gave I (R1 = Me, R2 = H, R3 = Ph, R4 =
     p-ClC6H4) (II).2HCl, m. 221.degree. (abs. EtOH-Et2O) [II.HCl, m.
     223-4.degree. (abs. EtOH.)]. The following I were similarly prepd. [R1,
     R2, R3, R3, m.p. (or b.p.), and m.p. of di-HCl salt (or other deriv.
     given)]: Me, H, Ph, p-Br C6H4, b0.5 161-71.degree., 249-50.degree.;
     H, Ph, Ph, 105-8.degree., 258-60.degree.; Me, H, Ph, p-MeOC6H4, b0.7
     168-9.degree., 194-5.degree.; Me, H, p-ClC6H4, p-ClC6H4, -,
     245-6.degree.; HOCH2CH2, H, Ph, Ph, -, 229.degree.; Et, H, Ph, Ph, -,
      241.degree. (decompn.); Me2NCH2CH2, H, Ph, Ph, b0.7 158-62.degree.,
     255-7.degree. (decompn.); Me, H, Ph, p-IC6H4, b0.5 181.degree., 260-1.degree. (mono-HCl salt); H, H, Ph, Ph, 70-2.degree. (b1
      183-90.degree.), 195.degree. (decompn.) (d-tartaric acid salt); Me, H, Ph,
      2-pyridyl, 95-7.degree., -; Me, H, Ph, p-FC6H4, b0.6 140-1.degree.,
      230-1.degree. (mono-HCl salt); Me, H, Ph, p-MeC6H4, b1 159-60.degree.,
      228-9.degree. (mono-HCl salt); Me, H, p-ClC6H4, cyclohexyl, -,
     278-9.degree. (decompn.); Et, H, Ph, p-ClC6H4, -, 227.5-8.0.degree.; Me,
     H, Ph, .omicron.-ClC6H4, b2 179-80.degree., 272-3.degree. (mono-HCl salt);
     Me, H, Ph, 2-thienyl, -, 202.degree. (decompn.); Bu, H, Ph, Ph, -,
      248.degree. (decompn.); Bu, H, Ph, p-ClC6H4, -, 253.5-5.0.degree. (di-HBr
      salt); Me, H, Ph, m-ClC6H4, b1.5 177.degree., 249-50.degree. (mono-HCl
      salt); HOCH2, H, Ph, Ph, -, 189-90.degree.; Me, H, p-ClC6H4, 2-thienyl, -,
      216.degree. (decompn.) (dioxalate); HO(CH2)4, H, Ph, p-ClC6H4, -,
      211-12.degree. (decompn.); Me, Me, Ph, Ph, b0.7 162-5.degree.,
     203-5.degree. (contg. 1 H2O); H2NC(:NH), H, Ph, Ph, -, 294-5.degree.
      (sulfate); EtO2C, H, Ph, p-ClC6H4, -, -; EtO2C, H, Ph, Ph, 114.degree., -.
     Other compds. reported were: II, b0.1 150-2.degree.; II.MeI, m.
      119-20.degree. (decompn.); HO(CH2)4N.CH2.CH2.N(CO2Et).CH2.CH2, b0.4
      168.degree. (mono-HCl salt, m. 118-19.degree.); p-FC6H4CHPhCl, b1,
     125-7.degree.; p-IC6H4CHPhCl, b0.6 148-9.degree.; .alpha.-(2-
     pyridyl)benzyl chloride, b0.3 126-31.degree.; .alpha.-cyclohexyl-p-
      chlorobenzyl chloride, b1.0 134-6.degree.; .alpha.-(2-thienyl)-p-
     chlorobenzyl chloride, unstable oil; p-ClC8H4ChPhN(CH2CH2Cl)2 HCl salt, m.
     135-7.degree.; p-ClC6H4CHPhN(CH2CH2OH)2, b0.1 197-207.degree.;
      .alpha.-cyclohexyl-p-chlorophenylmethanol, b0.7 122-5.degree. m.
     70-1.degree.; .alpha.-(2-thienyl)-p-chlorobenzyl alc., b0.3 157-8.degree.,
     m. 58.5-60.0.degree.; Ph2CMeNH2, b4 140-2.degree. (di-HCl salt, m.
     245-6.degree.); BuN.CH2.CH2. NH.CH2.CH2, b. 192-5.degree.;
     HO(CH2)4N.CH2.CH2.NH.CH2. CH2, b6 142.degree.; p-
     ClC6H4CHPhN.CH2.CH2.O.CH2.CH2, b0.3 162-5.degree..
·IT
     80476-89-7, 1-Piperazinecarboxylic acid, 4-(p-chloro-.alpha.-
```

Page 22

L8 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 1958:88366 CAPLUS

DN 52:88366

OREF 52:15598e-i,15599a-c

TI Benzhydryl carbalkoxy piperazines

IN Weston, Arthur W.; Hamlin, Kenneth E.

PA Abbott Laboratories

DT Patent

LA Unavailable

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 2819269 19580107 US

N-Benzhydryl-N1'-carbalkoxypiperazines of the formula AΒ R2R3R4CN.CH2.CH2.NR1.CH2.CH2, where R1 is a 1-4 C atom carbalkoxy group, R2 is H or 1-4 C atom alkyl, R3 is phenyl or halophenyl and R4 is phenyl, halophenyl, pyridyl, thienyl or cyclohexyl, are prepd. by treating a benzhydryl halide with an N-carbalkoxypiperazine. N-Carbethoxypiperazine (1) (29.8 g.), 46.5 g. benzhydryl bromide, 21.2 g. Na2CO3, and 125 cc. dry xylene are refluxed 4 hrs. to yield N-benzhydryl-N'-carbethoxypiperazine (II), m. 114.degree.. II refluxed with concd. HCl or KOH yields N-benzhydrylpiperazine (III); e.g., 14 g. II and 56 g. KOH are refluxed 22 hrs. in 250 cc. 95% EtOH, the EtOH is removed in vacuo and the residue treated with H2O, extd. with Et2O and the extract dried. III distils at 183-90.degree./1 mm. and then crystallizes, m. 70-2.degree.. The d-tartrate of III, after recrystn. (abs. EtOH) melts at 195.degree. (decompn.). I, after refluxing with p-chlorobenzhydryl chloride in PhMe in presence of NaHCO3, drying and treating with dry HCl gives the white solid N-(p-chlorobenzhydryl)-N'-carbethoxypiperazine-2HCl. This can be hydrolyzed and decarboxylated, by refluxing with concd. HCl, to the N-p-chlorobenzhydrylpiperazine (IV), b. 224.degree./1 mm. Benzhydrylpiperazines with the R1 = Me or Et may be prepd. by reacting the desired piperazine with HCHO (or its polymer) or MeCHO in conjunction with HCO2H. Thus 30 g. IV, 10.3 g. 35% HCHO, and 7.6 g. 90% HCO2H are heated 3 hrs. on a steam bath and then refluxed 4.5 hrs.; 7.7 g. concd. HCl is added and excess HCHO and HCO2H distd. in vacuo. The residue is dissolved in H2O and made alk. with aq. 40% NaOH. The sepd. oil is extd. 3 times with C6H6, the extracts concd., and the residue distd. N-(p-Chlorobenzhydryl)-N'-methylpiperazine (V) distd. at 178-81.degree./1 mm.; HCl salt, m. 221-2.degree.. The N'-ethylated roduct is prepd. similarly; the di-HCl salt, m. 227-8.degree.. Zn and HCl or Raney Ni in abs. EtOH may be used instead of HCO2H to reduce the aldehyde. The N'-alkylated compds. are useful in combating symptoms of histamine activity.

RN 111585-42-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(p-chloro-.alpha.-phenylbenzyl)-, ethyl ester, dihydrochloride (6CI) (CA INDEX NAME)

●2 HCl

L8 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 1958:24801 CAPLUS

DN 52:24801

OREF 52:4417e-g

TI Nonaqueous titration of 1,4-disubstituted piperazines

AU Ciaccio, L. L.; Missan, S. R.; McMullen, W. H.; Grenfell, T. C.

CS Chas. Pfizer & Co., Inc., Brooklyn, NY

SO Anal. Chem. (1957), 29, 1670-3 CODEN: ANCHAM; ISSN: 0003-2700

DT Journal

LA Unavailable

AB Potentiometric titrations of some 1,4-disubstituted derivs. with HClO4 in HOAc give 1 end point in HOAc solvent, but both end points in MeCN or MeNO2. The efficacy of 1,4-substituents in reducing strength decreases in the order EtOOC > Ph > p-chlorobenzhydryl > PhCH2, HOCH2CH2OCH2CH2, H. Thus, 4-substituted 1-carbethoxypiperazines are monobasic, 1,4-diphenylpiperazine gives 2 end points in HOAc and 1 in the weaker acid solvent MeNO2, and piperazine gives 1 end point corresponding to a dibasic base. By appropriate solvent choice differentiation according to base strength is possible.

IT 80476-89-7, 1-Piperazinecarboxylic acid, 4-(p-chloro-.alpha.phenylbenzyl)-, ethyl ester
 (titration of)

RN 80476-89-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, ethyl ester (9CI) (CA INDEX NAME)

ANSWER 10 OF 11 CAPLUS COPYRIGHT 2003 ACS

L8

```
AN
     1957:52175 CAPLUS
     51:52175
DN
OREF 51:9717a-i,9718a-c
TI
     N, N'-Disubstituted-piperazines
     Abbott Laboratories
PA
DT
     Patent
LA
     Unavailable
FAN.CNT 1
     PATENT NO.
                     KIND DATE
                                                 APPLICATION NO. DATE
      -----
                                                  -----
     GB 752331
PΙ
                                 19560711
                                                 GB
AΒ
     N,N'-Disubstituted-piperazines (I) were prepd. by treating Ph2CHCl or its
     substituted derivs. with substituted N-piperazines. Thus, refluxing and
     stirring a mixt. contg. 11.9 g. Ph(p-ClC6H4)CHCl, 50 g.
     N-methylpiperazine, and 5.3 g. Na2CO3 in 75 ml. anhyd. xylene 60 hrs.,
     extg. the hydrocarbon layer several times with dil. HCl, making the
     combined washings alk. with NaOH, extg. the oil with Et2O, drying, pptg.
     the di-HCl salt with gaseous HCl, and recrystg. from abs. EtOH-Et2O gave
     N-(p-chlorobenzhydryl)-N'-methylpiperazine, m. 220-1.degree.; HCl salt, m.
     223-4.degree.. Similarly were prepd. the following I (N- and
     N'-substituents, b.p., and, in parenthese, salt formed and its m.p.,
     given): Ph(p-BrC6H4)CH, Me, b0.5 161-71.degree. [di-HCl salt,
     249-50.degree. (from abs. EtOH)]; Ph2CH, Me, - (m. 105-8.degree.) [di-HCl
     salt, 258-60.degree. (from abs. EtOH)]; Ph(p-MeOC6H4)CH, Me, b0.7
     168-9.degree. [di-HCl salt, 194-5.degree. (from iso-PrOH-Et20)];
      (p-ClC6H4)2CH, Me, - [di-HCl salt, 245-6.degree. (from EtOH)]; Ph2CH,
     HOCH2CH2, - [di-HCl salt, 229.degree. (decompn.)]; Ph2CH, Et, - [di-HCl
     salt, 241.degree. (decompn.)]; Ph2CH, Me2NCH2CH2, - [di-HCl salt, m.
      255-7.degree. (decompn.) (from iso-PrOH-Et2O)]; Ph(p-IC6H4)CH, Me, b0.5
      181.degree. (HCl salt, 260-1.degree.); .alpha.-(2-pyridyl)benzyl, Me, m.
      95-7.degree.; Ph(p-FC6H4)CH, Me, b0.6 140-1.degree. (HCl salt,
      230-1.degree.); Ph(p-MeC6H4)CH, Me, b1.0 159-60.degree. [HCl salt,
      228-9.degree. (decompn.) (from abs. EtOH)]; C6H11(p-ClC6H4) CH, Me, -
      [di-HCl salt, 278-9.degree. (decompn.) (from EtOH)]; Ph(p-ClC6H4)CH, Et, - [di-HCl salt, 227.5-8.0.degree. (from EtOH-Et2O)]; Ph(o-ClC6H4)CH, Me,
     b2.0 179-80.degree. (HCl salt, 272-3.degree.); .alpha.-(2-thienyl)benzyl,
Me, - [di-HCl salt, 202.degree. (decompn.) (from EtOH-pentane)]; Ph2CH,
Bu, - [di-HCl salt, 248.degree. (decompn.) (from MeOHMe2CO)];
Ph(p-ClC6H4)CH, - [di-HBr salt, 253.5-5.0.degree. (from iso-PrOH)];
      Ph(m-ClC6H4)CH, Me, b1.5 177.degree. [HCl salt, 249-50.degree. (from abs.
     EtOH)]; Ph2CH, HOCH2, - [HCl salt, 189-90.degree. (from EtOH-Et2O)]; .alpha.-(2-thienyl)-p-chlorobenzyl, Me, - [dioxalate, 216.degree. (decompn.)]; Ph(p-ClC6H4)CH, HO(CH2)4, - [di-HCl salt, 211-12.degree.
      (decompn.) (from EtOH-Et2O)]; Ph2CMe, Me, b0.7 162-5.degree. [di-HCl
     salt-H2O, 203-5.degree. (from abs. EtOH)]; Ph2CH, guanyl, - [H2SO4 salt,
294-5.degree. (decompn.)]; Ph(p-ClC6H4)CH, Me, - [MeI salt, 119-20.degree.
      (decompn.) (from abs. EtOH)]; Ph(p-ClC6H4)CH, Me, b0.1 150-2.degree. [HCl
      salt, 223-4.degree. (decompn.)]. The following I were also prepd. (N- and
     N'-substituents shown; no phys. data reported): Ph2CH, iso-Pr; Ph2CH, iso-Bu; Ph2CH, HO(CH2)3; Ph2CH, Me2N(CH2)4; Ph2CH, Me2NCH2CH2; Ph2CEt, Me; Ph2CBu, Me; (p-IC6H4)2CH, Me; (o-ClC6H4)2CH, Me; p-ClC6H4(p-BrC6H4)CH, Me;
     p-BrC6H4 (p-MeOC6H4) CH, Me; p-ClC6H4 (p-MeC6H4) CH, Me; (p-MeC6H4) 2CH, Me;
      (p-MeOC6H4)2CH, Me; .alpha.-cyclopentylbenzyl, Me; .alpha.-(2-
     pyrimidyl)benzyl, Me; .alpha.-(2-furyl)benzyl, Me; Ph(p-ClC6H4)CH, EtO2C.
      Intermediates for the prepn. of I by alternative methods are given. Thus,
     refluxing 29.8 g. N-carbethoxypiperazine, 46.5 g. Ph2CHBr, and 21.2 g.
     Na2CO3 in 125 ml. xylene gave N-benzhydryl-N'-carbethoxypiperazine(II),m,
      114-15.degree.. Refluxing 14 g. II and 56 g. KOH in 250 ml. 95% EtOH 22
     hrs., concg. in vacuo, treating the residue with H2O, extg. with Et2O,
```

drying, and distg. gave N-benzhydrylpiperazine, b1.0 183-90.degree., which crystallizes and m. 70-2.degree.; d-tartaric acid salt, m. 195.degree. (decompn.) (from abs. EtOH). Refluxing 47.4 g. N-carbethoxypiperazine, 32.6 g. Cl(CH2)4OH, and 31.8 g. Na2CO3 in 150 ml. anhyd. EtOH 5 hrs. gave N-carbethoxy-N'-(4-hydroxybutyl)piperazine (III), b0.4 165-8.degree. (HCl salt, m. 118-19.degree.). Hydrolyzing 24 g. III in 100 ml. concd. HCl gave N-(4-hydroxybutyl)piperazine, b6.0 142.degree.. Dissolving 82 g. Ph(p-FC6H4)CHOH in 50 ml. C6H6 and 50 ml. n-hexane, mixing with excess CaCl2, treating with HCl, cooling, keeping the temp. at 12-25.degree., pouring the soln. over a fresh batch of CaCl2, repeating in 15 min., filtering, concg., and distg. the residue gave Ph(p-FC6H4)CHCl, b1.0 125-7.degree.. Similarly Ph(p-IC6H4) CHCl, b0.6 148-9.degree., was prepd. Treating a cooled mixt. of 24 g. .alpha.-(2-pyridyl)benzhydryl alc. HCl salt in 200 ml. anhyd. C6H6 with 36 g. SOCl2, stirring 1 hr., allowing to stand at room temp. 15 hrs., heating 1 hr. at 60.degree., concg. in vacuo, removing the excess SOCl2 by repeated addn. of anhyd. C6H6, distg. in vacuo, dissolving the residue in H2O, making alk. with Na2CO3, extg. with Et20, and distg. gave .alpha.-(2-pyridyl)benzhydryl chloride, b0.3 126-31.degree.. Refluxing 23.7 g. Ph(p-ClC6H4)CHCl, 10.5 g. (HOCH2CH2)2NH, and 10.6 g. Na2CO3 in 150 ml. dry PhMe 40 hrs., decanting the supernatant liquid, concg., and distg. the yellow oil gave Ph(p-ClC6H4)CHN(CH2CH2OH)2, b0.1 197-207.degree. (HCl salt, m. 135-7.degree.. Adding 70.3 g. p-ClC6H4CHO to a Grignard reagent prepd. from  $114.1\ \mathrm{g}.$  cyclohexyl bromide and  $14.4\ \mathrm{g}.$  Mg, decompg. the addn. complex with NH4Cl, extg. with Et2O, and distg. gave the carbinol, b0.7 122-5.degree., which on standing solidifies and m. 70-1.degree.; treatment with HCl gave .alpha.-cyclohexyl-p-chlorobenzyl chloride, b1.6 134-6.degree.. Similarly prepd. was the .alpha.-(2-thienyl) analog which decomp. on heating. Adding 45 g. MeCPh2CONH2 to an alk. hypobromite soln. prepd. from 33.6 g. Br and 82 g. KOH in 425 ml. cold H2O, stirring 1 hr. at 0.degree., gradually warming to room temp., then on a steam bath 30 min., extg. the yellow oil with Et20, drying, concg., and distg. the residue gave MeCPh2NH2, b4 140-2.degree.; HCl salt, m. 245-6.degree.. Refluxing 33 g. N-carbethoxy-N'-butylpiperazine in 170 ml. concd. HCl 42 hrs., concg. in vacuo, dissolving the residue in warm H2O, making alk. with 50% KOH, extg. the oil layer with Et20, drying, and distg. gave N-butylpiperazine, b747 192-5.degree.. The compds. are useful in combating symptoms of histamine and have antispasmodic activity.

IT 80476-89-7, 1-Piperazinecarboxylic acid, 4-(p-chloro-.alpha.-phenylbenzyl)-, ethyl ester

(prepn. of)

RN 80476-89-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, ethyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2003 ACS 1957:30115 CAPLUS AN DN 51:30115 OREF 51:5847a-b TI N-Diarylmethylpiperazines Abbott Laboratories PA DT Patent LA Unavailable FAN.CNT 1 · PATENT NO. KIND DATE APPLICATION NO. DATE ----------PΙ GB 752332 19560711 ĢΒ GI For diagram(s), see printed CA Issue. AB by refluxing with concd. HCl or KOH in EtOH. Thus, p-

AB N-Diarylmethyl-N'-carbalkoxypiperazines were hydrolyzed and decarboxylated by refluxing with concd. HCl or KOH in EtOH. Thus, p-ClC6H4PhCHN.(CH2)2.N(CO2Et).CH2.CH2, prepd. from N-carbethoxypiperazine and 4-ClC6H4PhCHCl refluxed with concd. HCl gave N-p-chlorobenzhydrylpiperazine. Similarly, N-benzhydryl-N'-carbethoxypiperazine refluxed 22 hrs. in KOH-EtOH gave benzhydrylpiperazine, b1 183-90.degree., m. 70-2.degree..

IT 80476-89-7, 1-Piperazinecarboxylic acid, 4-(p-chloro-.alpha.-

RN 80476-89-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, ethyl ester (9CI) (CA INDEX NAME)

=> file caold
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

50.73 215.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL ENTRY SESSION

CA SUBSCRIBER PRICE

-7.16 -7.16

FILE 'CAOLD' ENTERED AT 16:11:27 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 18

L9 7 L7

=> d 19 1-7 bib hitstr

```
ANSWER 1 OF 7 CAOLD COPYRIGHT 2003 ACS
L9
AN . CA54:12169h CAOLD
    substituted methylpiperazines
TI
ΑU
    Janssen, Paul A. J.
DT
    Patent
    PATENT NO.
                 KIND
                             DATE
    -----
ΡI
    BE 539693
IT
   80476-89-7
    80476-89-7 CAOLD
RN
    1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, ethyl
CN
    ester (9CI) (CA INDEX NAME)
```

L9 ANSWER 2 OF 7 CAOLD COPYRIGHT 2003 ACS

AN CA53:21986f CAOLD

TI unsymmetrically substituted piperazines - (XII) benzhydrylpiperazines and related compds. with spasmolytic and antifibrillatory action

AU Ide, Walter S.; Lorz, E.; Phillips, A. P.; Russell, P. B.; Baltzly, R.; Blumfeld, R.

IT 112350-85-3

RN 112350-85-3 CAOLD

CN 1-Piperazinecarboxylic acid, 4-(o-methyl-.alpha.-phenylbenzyl)-, ethyl ester, hydrochloride (6CI) (CA INDEX NAME)

HCl

```
ANSWER 3 OF 7 CAOLD COPYRIGHT 2003 ACS
L9
AN
    CA53:7215f CAOLD
TI
    piperazine derivs.
    Weston, Arthur W.; Hamlin, K. E.
ΑU
PΑ
    Abbott Laboratories
DT
    Patent
    PATENT NO.
                  KIND
                              DATE
    -----
    US 2861072
                              1958
ΡI
IT
   80476-89-7
    80476-89-7 CAOLD
RN
CN
    1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, ethyl
    ester (9CI) (CA INDEX NAME)
```

L9 AN TI AU	ANSWER 4 OF 7 CAOLD COPYRIGHT 2003 ACS CA52:15598e CAOLD benzhydryl carbalkoxy piperazines Weston, Arthur W.; Hamlin, K. E.
PA	Abbott Laboratories
DT	Patent
	PATENT NO. KIND DATE
PI	US 2819269 1958
IT	111585-42-3
RN	111585-42-3 CAOLD
CN	1-Piperazinecarboxylic acid, 4-(p-chloroalphaphenylbenzyl)-, ethyl ester, dihydrochloride (6CI) (CA INDEX NAME)

●2 HCl

```
L9 ANSWER 5 OF 7 CAOLD COPYRIGHT 2003 ACS
AN CA52:4417f CAOLD
TI nonaq. titration of 1,4-disubstituted piperazines
AU Ciaccio, L. L.; Missan, S. R.; McMullen, W. H.; Grenfell, T. C.
IT 80476-89-7
RN 80476-89-7 CAOLD
CN 1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, ethylester (9CI) (CA INDEX NAME)
```

L9 ANSWER 6 OF 7 CAOLD COPYRIGHT 2003 ACS

AN CA51:9717a CAOLD

TI N,N'-disubstituted-piperazines

PA Abbott Laboratories

DT Patent

PATENT NO. KIND DATE

PI GB 752331

IT 80476-89-7 111585-42-3

RN 80476-89-7 CAOLD

CN 1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 111585-42-3 CAOLD

CN 1-Piperazinecarboxylic acid, 4-(p-chloro-.alpha.-phenylbenzyl)-, ethyl ester, dihydrochloride (6CI) (CA INDEX NAME)

•2 HCl

```
ANSWER 7 OF 7 CAOLD COPYRIGHT 2003 ACS
L9
    CA51:5847a CAOLD
AN
    N-diarylmethylpiperazines
TI
    Abbott Laboratories
PΑ
DT
    Patent
    PATENT NO.
                 KIND
                             DATE
    -----
    GB 752332
PΙ
IT 80476-89-7
    80476-89-7 CAOLD
RN
    1-Piperazinecarboxylic acid, 4-[(4-chlorophenyl)phenylmethyl]-, ethyl
CN
    ester (9CI) (CA INDEX NAME)
```

=> log h COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.74	234.55
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.16

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:12:13 ON 16 JUL 2003